Ally
385 posts






Philippines' House of Representatives Investigates 290K+ Excess Deaths Correlated with Experimental Vaccines Back in 2022 After I raised the excess deaths in the UK following the Covid Jab rollout. The Gov. response was to get the ONS to increase the number of ‘expected deaths’






New paper from the Prusty group: SARS-CoV-2 spike protein reactivates latent herpesviruses in Long COVID patients 🦠 In this new paper, the authors argue that many cases of Long COVID may be caused by the SARS-CoV-2 spike protein changing cellular metabolism, in a way that allows normally latent (inactive) herperviruses to reactivate. We all have various herpesviruses in our body. Depending on genetics and several other factors which have yet to be identified by science, most of the time our immune systems are able to keep these viruses suppressed, even though they remain hidden in the body in an inactive state after we contract them. However, sometimes something can shift in our internal environment that interrupts our immune systems' ability to keep the virus suppressed. Here the Prusty group argues that in Long COVID, spike protein is affecting the way our cells function in a way that allows normally latent viruses such as human herpesvirus 6, human herpesvirus 7, and Epstein–Barr virus to reactivate. They discuss possible antiviral treatments, with some caveats. They write, "Anti-herpesvirus drugs may be therapeutically relevant for carefully selected long COVID or ME/CFS subgroups with clear evidence of herpesvirus reactivation, particularly EBV, HHV-6, CMV, VZV, or HSV. However, they should not be viewed as broadly applicable treatments in unstratified patients. Existing ME/CFS studies with artesunate, valganciclovir, or valacyclovir suggest possible benefit in virus-reactivation-defined subsets [143], while long COVID evidence remains more inferential. A key therapeutic dilemma is that different herpesviruses have different antiviral susceptibilities, so covering EBV/HHV-6/CMV versus HSV/VZV may require different or combined regimens, increasing complexity, toxicity risk, and the need for precise virological diagnostics before treatment." What this means is that while sometimes antivirals can help, we need much better diagnostics to pinpoint which patients need which drugs. Research from ME/CFS, which in many cases also appears to involve reactivation of latent viruses, shows that select subgroups of patients can respond to certain drugs - but it really depends on which virus you have, as available drugs do not work on all of the viruses. You really have to know which one you're treating, and be mindful of the risk of side effects. Additionally, they write that SARS-CoV-2 persistence may be the ultimate root cause reason as to why these viruses reactivate- so ultimately, we will need diagnostics for that as well. While we unfortunately have a ways to go in developing biomarkers, it's great to see the issues of SARS-CoV-2 persistence and latent virus reactivation receiving more attention in a mainstream publication like Cell. Thank you to the authors for this important work! 🙏 cell.com/trends-open/fu…









The government suggests people consult patient information leaflets before taking folic acid. When do we get the patient information leaflets for each loaf of bread? When do we get one for 'organic' sausages?




